company background image
PTCT

PTC Therapeutics NasdaqGS:PTCT Stock Report

Last Price

US$49.16

Market Cap

US$3.5b

7D

-6.9%

1Y

25.1%

Updated

23 Sep, 2022

Data

Company Financials +
PTCT fundamental analysis
Snowflake Score
Valuation4/6
Future Growth1/6
Past Performance0/6
Financial Health1/6
Dividends0/6

PTCT Stock Overview

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders.

PTC Therapeutics Competitors

Price History & Performance

Summary of all time highs, changes and price drops for PTC Therapeutics
Historical stock prices
Current Share PriceUS$49.16
52 Week HighUS$55.58
52 Week LowUS$25.01
Beta0.58
1 Month Change-7.39%
3 Month Change22.23%
1 Year Change25.12%
3 Year Change42.00%
5 Year Change145.68%
Change since IPO198.12%

Recent News & Updates

Aug 05

PTC Therapeutics betas topline expectations, strengthens commercial portfolio

PTC Therapeutics (NASDAQ:PTCT) shows a 42% growth in revenue to $166M. Revenue includes net product revenue across the commercial portfolio of $143.7M vs. $103.1M last year. Royalty revenue of $21.8M vs. $13.6M. Bifurcating: Translarna net product revenues were $77M vs. $52.6M; Emflaza net product revenues were $56.8M vs. $49.1M. GAAP R&D expenses were $157.3M vs. $125.5M; GAAP SG&A expenses were $79.9M vs. $68.9M. Net loss was $152.1M vs. $118.4M. Cash, cash equivalents, and marketable securities was $505.5M on June 30, 2022, compared to $773.4M on Dec. 31, 2021. Reaffirms FY guidance: Total revenues between $700M-750M; net product revenues for the DMD franchise between $475M-495M. R&D and SG&A expense for the full year 2022 to be between $915M-965M. GAAP EPS of -$2.13 misses consensus by $0.76. "We made significant progress in the second quarter toward achieving our ambitious goals for 2022. We continued to generate strong revenue growth, to expand our product portfolio, and to advance our pipeline. PTC has a broad and deep pipeline across a range of diseases, and we eagerly anticipate important results for several registration-directed studies during the next six to twelve months and this will continue our transformational growth." said Stuart W. Peltz, Ph.D., CEO. Stock gets a sell-side rating of Buy with 3.63 score and price target of $49.9. Quant rating of Hold with lowest factor grades to valuation and growth. Contributor who gives sell rating to the stock writes: 'DMD Trial News Unlikely To Restore Flagging Share Price' Previously: PTC Therapeutics Q2 GAAP EPS misses, revenue beats, FY22 guidance reaffirmed (Aug. 4)

Shareholder Returns

PTCTUS BiotechsUS Market
7D-6.9%-5.0%-5.2%
1Y25.1%-30.0%-23.1%

Return vs Industry: PTCT exceeded the US Biotechs industry which returned -30.9% over the past year.

Return vs Market: PTCT exceeded the US Market which returned -21.6% over the past year.

Price Volatility

Is PTCT's price volatile compared to industry and market?
PTCT volatility
PTCT Average Weekly Movement5.4%
Biotechs Industry Average Movement11.1%
Market Average Movement6.9%
10% most volatile stocks in US Market15.9%
10% least volatile stocks in US Market2.8%

Stable Share Price: PTCT is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 5% a week.

Volatility Over Time: PTCT's weekly volatility (5%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
19981,172Stuart Peltzhttps://www.ptcbio.com

PTC Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders. Its portfolio pipeline includes commercial products and product candidates in various stages of development, including clinical, pre-clinical and research and discovery stages, focuses on the development of treatments for multiple therapeutic areas, such as rare diseases. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy in the European Economic Area and the United States, as well as to treat nonsense mutation Duchenne muscular dystrophy in Brazil and Russia; commercializes Tegsedi and Waylivra for the treatment of rare diseases in Latin America and the Caribbean; and markets Evrysdi for the treatment of spinal muscular atrophy in adults and children two months and older in Brazil.

PTC Therapeutics Fundamentals Summary

How do PTC Therapeutics's earnings and revenue compare to its market cap?
PTCT fundamental statistics
Market CapUS$3.52b
Earnings (TTM)-US$555.70m
Revenue (TTM)US$618.24m

5.7x

P/S Ratio

-6.3x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
PTCT income statement (TTM)
RevenueUS$618.24m
Cost of RevenueUS$575.99m
Gross ProfitUS$42.25m
Other ExpensesUS$597.95m
Earnings-US$555.70m

Last Reported Earnings

Jun 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-7.77
Gross Margin6.83%
Net Profit Margin-89.89%
Debt/Equity Ratio-237.3%

How did PTCT perform over the long term?

See historical performance and comparison
We’ve recently updated our valuation analysis.

Valuation

Is PTCT undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

4/6

Valuation Score 4/6

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Below Fair Value

  • Significantly Below Fair Value

  • Analyst Forecast

Key Valuation Metric

Which metric is best to use when looking at relative valuation for PTCT?

Other financial metrics that can be useful for relative valuation.

PTCT key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue5.8x
Enterprise Value/EBITDA-11.8x
PEG Ration/a

Price to Sales Ratio vs Peers

How does PTCT's PS Ratio compare to its peers?

PTCT PS Ratio vs Peers
The above table shows the PS ratio for PTCT vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyPSEstimated GrowthMarket Cap
Peer Average17.2x
BPMC Blueprint Medicines
17x41.5%US$3.9b
DNLI Denali Therapeutics
29.8x34.6%US$3.4b
FOLD Amicus Therapeutics
8.8x25.0%US$2.8b
ARWR Arrowhead Pharmaceuticals
13.1x27.8%US$3.3b
PTCT PTC Therapeutics
5.7x11.9%US$3.5b

Price-To-Sales vs Peers: PTCT is good value based on its Price-To-Sales Ratio (5.7x) compared to the peer average (17.2x).


Price to Earnings Ratio vs Industry

How does PTCT's PE Ratio compare vs other companies in the US Biotechs Industry?

Price-To-Sales vs Industry: PTCT is good value based on its Price-To-Sales Ratio (5.7x) compared to the US Biotechs industry average (13x)


Price to Sales Ratio vs Fair Ratio

What is PTCT's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

PTCT PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio5.7x
Fair PS Ratio2.8x

Price-To-Sales vs Fair Ratio: PTCT is expensive based on its Price-To-Sales Ratio (5.7x) compared to the estimated Fair Price-To-Sales Ratio (2.8x).


Share Price vs Fair Value

What is the Fair Price of PTCT when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: PTCT ($49.16) is trading below our estimate of fair value ($244.63)

Significantly Below Fair Value: PTCT is trading below fair value by more than 20%.


Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Target price is less than 20% higher than the current share price.


Discover undervalued companies

Future Growth

How is PTC Therapeutics forecast to perform in the next 1 to 3 years based on estimates from 13 analysts?

Future Growth Score

1/6

Future Growth Score 1/6

  • Earnings vs Savings Rate

  • Earnings vs Market

  • High Growth Earnings

  • Revenue vs Market

  • High Growth Revenue

  • Future ROE


56.2%

Forecasted annual earnings growth

Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: PTCT is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: PTCT is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: PTCT is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: PTCT's revenue (11.9% per year) is forecast to grow faster than the US market (7.6% per year).

High Growth Revenue: PTCT's revenue (11.9% per year) is forecast to grow slower than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: PTCT is forecast to be unprofitable in 3 years.


Discover growth companies

Past Performance

How has PTC Therapeutics performed over the past 5 years?

Past Performance Score

0/6

Past Performance Score 0/6

  • Quality Earnings

  • Growing Profit Margin

  • Earnings Trend

  • Accelerating Growth

  • Earnings vs Industry

  • High ROE


-37.9%

Historical annual earnings growth

Earnings and Revenue History

Quality Earnings: PTCT is currently unprofitable.

Growing Profit Margin: PTCT is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: PTCT is unprofitable, and losses have increased over the past 5 years at a rate of 37.9% per year.

Accelerating Growth: Unable to compare PTCT's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: PTCT is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (29.2%).


Return on Equity

High ROE: PTCT's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.


Discover strong past performing companies

Financial Health

How is PTC Therapeutics's financial position?

Financial Health Score

1/6

Financial Health Score 1/6

  • Short Term Liabilities

  • Long Term Liabilities

  • Debt Level

  • Reducing Debt

  • Stable Cash Runway

  • Forecast Cash Runway

Financial Position Analysis

Short Term Liabilities: PTCT has negative shareholder equity, which is a more serious situation than short term assets not covering short term liabilities.

Long Term Liabilities: PTCT has negative shareholder equity, which is a more serious situation than short term assets not covering long term liabilities.


Debt to Equity History and Analysis

Debt Level: PTCT has negative shareholder equity, which is a more serious situation than a high debt level.

Reducing Debt: PTCT's has negative shareholder equity, so we do not need to check if its debt has reduced over time.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: PTCT has sufficient cash runway for more than a year based on its current free cash flow.

Forecast Cash Runway: Insufficient data to determine if PTCT has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.


Discover healthy companies

Dividend

What is PTC Therapeutics's current dividend yield, its reliability and sustainability?

Dividend Score

0/6

Dividend Score 0/6

  • Notable Dividend

  • High Dividend

  • Stable Dividend

  • Growing Dividend

  • Earnings Coverage

  • Cash Flow Coverage

Dividend Yield vs Market

Notable Dividend: Unable to evaluate PTCT's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate PTCT's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if PTCT's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if PTCT's dividend payments have been increasing.


Earnings Payout to Shareholders

Earnings Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Cash Payout to Shareholders

Cash Flow Coverage: Unable to calculate sustainability of dividends as PTCT has not reported any payouts.


Discover strong dividend paying companies

Management

How experienced are the management team and are they aligned to shareholders interests?

3.5yrs

Average management tenure


CEO

Stuart Peltz (62 yo)

24.67yrs

Tenure

US$11,022,323

Compensation

Dr. Stuart W. Peltz, Ph D., co-founded PTC Therapeutics Inc. in 1998 and has been its Chief Executive Officer since 1998. Dr. Peltz has been Independent Director of Health Sciences Acquisitions Corporation...


CEO Compensation Analysis

Compensation vs Market: Stuart's total compensation ($USD11.02M) is above average for companies of similar size in the US market ($USD6.80M).

Compensation vs Earnings: Stuart's compensation has increased whilst the company is unprofitable.


Leadership Team

Experienced Management: PTCT's management team is considered experienced (3.5 years average tenure).


Board Members

Experienced Board: PTCT's board of directors are seasoned and experienced ( 16.8 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: PTCT insiders have only sold shares in the past 3 months.


Recent Insider Transactions

NasdaqGS:PTCT Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
09 Aug 22SellUS$118,522Stephanie OkeyIndividual2,296US$51.62
09 Jun 22SellUS$20,074Dawn SvoronosIndividual738US$27.20
07 Jun 22SellUS$10,919Stuart PeltzIndividual407US$26.83
19 Apr 22SellUS$34,947Eric PauwelsIndividual822US$42.52
19 Apr 22SellUS$38,136Matthew KleinIndividual897US$42.52
14 Apr 22SellUS$3,713Stuart PeltzIndividual82US$45.28
01 Feb 22SellUS$25,281Neil AlmsteadIndividual632US$40.00
01 Feb 22SellUS$89,724Stuart PeltzIndividual2,243US$40.00
01 Feb 22SellUS$31,162Mark BouldingIndividual779US$40.00
01 Feb 22SellUS$14,681Eric PauwelsIndividual367US$40.00
01 Feb 22SellUS$12,521Christine UtterIndividual313US$40.00
01 Feb 22SellUS$22,121Emily HillIndividual553US$40.00
25 Jan 22SellUS$8,295Emily HillIndividual211US$39.31
25 Jan 22SellUS$1,691Neil AlmsteadIndividual43US$39.31
25 Jan 22SellUS$12,974Stuart PeltzIndividual330US$39.31
25 Jan 22SellUS$14,114Eric PauwelsIndividual359US$39.31
07 Jan 22SellUS$19,648Dawn SvoronosIndividual510US$38.53
07 Jan 22SellUS$30,820Emily HillIndividual800US$38.53
07 Jan 22SellUS$34,095Mark BouldingIndividual885US$38.53
07 Jan 22SellUS$28,778Christine UtterIndividual747US$38.53
07 Jan 22SellUS$30,859Neil AlmsteadIndividual801US$38.53
07 Jan 22SellUS$29,857Matthew KleinIndividual775US$38.53
07 Jan 22SellUS$83,330Stuart PeltzIndividual2,163US$38.53
07 Jan 22SellUS$33,363Eric PauwelsIndividual866US$38.53
04 Jan 22SellUS$15,559Stuart PeltzIndividual378US$41.16
04 Jan 22SellUS$7,121Emily HillIndividual173US$41.16
04 Jan 22SellUS$33,177Eric PauwelsIndividual806US$41.16
04 Jan 22SellUS$2,634Neil AlmsteadIndividual64US$41.16

Ownership Breakdown

Dilution of Shares: Shareholders have not been meaningfully diluted in the past year.


Top Shareholders

Top 25 shareholders own 93.54% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
14.96%
FMR LLC
10,700,782$526.1m-0.25%0.05%
10.04%
The Vanguard Group, Inc.
7,183,692$353.2m3.61%0.01%
9.83%
Wellington Management Group LLP
7,033,505$345.8m-13.71%0.06%
8.35%
BlackRock, Inc.
5,972,622$293.6m-4.37%0.01%
7.05%
RTW Investments, LP
5,045,307$248.0m-3.37%5.22%
6.84%
Franklin Resources, Inc.
4,890,895$240.4m-0.04%0.1%
5.07%
State Street Global Advisors, Inc.
3,624,877$178.2m13.85%0.01%
4.61%
Armistice Capital LLC
3,296,000$162.0m8.56%4%
3.42%
Camber Capital Management LP
2,450,000$120.4m40%5.25%
2.99%
Janus Henderson Group plc
2,135,676$105.0m-20.37%0.06%
2.36%
Macquarie Investment Management Business Trust
1,688,734$83.0m11.38%0.09%
2.29%
T. Rowe Price Group, Inc.
1,640,986$80.7m-4.51%0.01%
2.29%
Loomis Sayles & Company, L.P.
1,636,835$80.5m-0.6%0.15%
1.94%
Section Six Partners, L.P.
1,386,594$68.2m0%no data
1.86%
Geode Capital Management, LLC
1,333,519$65.6m3.28%0.01%
1.42%
BNY Mellon Asset Management
1,017,870$50.0m-4.55%0.01%
1.33%
D. E. Shaw & Co., L.P.
952,787$46.8m-8.16%0.09%
1.15%
Jacobs Levy Equity Management Inc
822,094$40.4m29.87%0.32%
1.01%
J.P. Morgan Asset Management, Inc.
725,363$35.7m-2.62%0.01%
0.96%
TimesSquare Capital Management, LLC
685,900$33.7m-19.15%0.41%
0.92%
Northern Trust Global Investments
655,569$32.2m-2.49%0.01%
0.87%
Handelsbanken Asset Management
621,300$30.5m36.85%0.06%
0.74%
Charles Schwab Investment Management, Inc.
528,538$26.0m3.15%0.01%
0.66%
Redwood Investments, LLC
471,978$23.2m32.7%2.53%
0.58%
Norges Bank Investment Management
414,626$20.4m0%no data

Company Information

PTC Therapeutics, Inc.'s employee growth, exchange listings and data sources


Key Information

  • Name: PTC Therapeutics, Inc.
  • Ticker: PTCT
  • Exchange: NasdaqGS
  • Founded: 1998
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Implied Market Cap: US$3.517b
  • Shares outstanding: 71.54m
  • Website: https://www.ptcbio.com

Number of Employees


Location

  • PTC Therapeutics, Inc.
  • 100 Corporate Court
  • South Plainfield
  • New Jersey
  • 7080
  • United States


Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
PTCTNasdaqGS (Nasdaq Global Select)YesCommon StockUSUSDJun 2013
BH3DB (Deutsche Boerse AG)YesCommon StockDEEURJun 2013

Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2022/09/23 00:00
End of Day Share Price2022/09/23 00:00
Earnings2022/06/30
Annual Earnings2021/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.